The latest Investing Matters Podcast episode with multi-award-winning fund manager and international bestselling author Lee Freeman-Shor has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,035.00
Bid: 4,059.00
Ask: 4,062.00
Change: -55.00 (-1.34%)
Spread: 3.00 (0.074%)
Open: 4,098.00
High: 4,120.00
Low: 4,035.00
Prev. Close: 4,090.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IMS and announcement of disposal

1 Nov 2012 07:00

RNS Number : 0369Q
Croda International PLC
01 November 2012
 



 

1 November 2012

 

 

Croda International Plc

 

 

Interim Management Statement and announcement of disposal

 

 

Croda International Plc ("Croda") today announces its interim management statement for the period since 1 July 2012 and the disposal of its Italian business based in Cremona. All figures in this statement, including those for the comparative periods, exclude this business which will be treated as discontinued in the full year accounts.

 

Trading

 

Trading in the third quarter was robust considering the depressed market conditions, particularly in Europe. Underlying* Group sales were up 3.2% compared to 2011.

 

Month to month trading has been volatile: sales were in line with expectations in July and August but trading weakened in September, usually a strong month. Adverse currency translation averaged 2.8% but the exit rate for the quarter was 6.2%. Including the adverse currency impact, continuing sales were up 0.5% at £256.5m (2011: £255.2m). As in previous quarters, we saw turnover decline in Europe but experienced growth in all other major regions. Volumes were up 8.9% overall but the strongest growth came in lower value products in Performance Technologies and Industrial Chemicals (which were weak in the third quarter of 2011). This meant that average selling prices fell by 5.7%. We fully recovered raw material inflation.

 

Despite an adverse mix, operating margins increased to 23.3% (2011: 22.3%). As a result, continuing operating profit increased 4.7% to £59.7m (2011: £57.0m) and continuing pre-tax profit increased 4.4% to £59.3m (2011: £56.8m).

 

Against a very strong third quarter in 2011, Consumer Care sales were down 2.7% due to slow Personal Care sales, particularly in Europe. Health Care and Crop Care both saw sales increase in the quarter. Return on sales grew 2.5 percentage points to 31.4% driven primarily by a number of successful product launches but also due to a lower allocation of central costs as a consequence of the reduced turnover. This resulted in operating profit growth of 5.7% to £44.2m (2011: £41.8m).

 

Performance Technologies sales were up 2.5% at £94.7m (2011: £92.4m). We saw growth in all business sectors apart from Lubricant Additives. Again, we successfully launched a significant number of new products but the strongest growth in the quarter came from existing, lower margin, less differentiated products. The higher volumes relative to Consumer Care led to an increased allocation of central costs to this segment. These factors reduced overall return on sales to 14.1% (2011: 14.8%) and resulted in a profit reduction of 2.2% to £13.4m (2011: £13.7m).

 

Industrial Chemicals performed strongly with sales up 16.1% to £20.9m (2011: £18.0m). Profits in this sector increased 40.0% to £2.1m (2011: £1.5m).

 

Despite the soft trading environment in Europe and the currency headwinds, our operating profit for the year to date at £193.5m is 8.2% ahead of a strong 2011 comparative period. This continues to vindicate our strategy of concentrating on high value, niche markets with innovative technologies, supplying to customers both large and small around the world.

 

* Excluding acquisitions, disposals and currency

 

Financial Position

 

Net debt reduced by £5.8m to £202.2m in the quarter despite a £10.2m payment to the pension fund as part of the funding plan announced with the interim results.

 

There were no significant events or transactions during the period which resulted in a material impact on the financial position of the Group.

 

Disposal

 

We are announcing today the sale of our Italian business based in Cremona to a private company located in Italy for a consideration equivalent to the working capital value. Completion is subject to a number of minor conditions but is expected to take place before the year end. The business was acquired with Uniqema in 2006 and is focused on the manufacture of basic products for the Performance Technologies and Industrial Chemicals sectors. In the first nine months of the year it had a turnover of £25.4m (2011: £32.2m) and made an operating loss of £0.1m (2011: operating profit £4.1m). In the third quarter it had sales of £7.8m (2011: £10.4m) and broke even (2011: £0.6m profit).

 

Commenting on the outlook, Martin Flower, Chairman of Croda said:

 

"Quarter four has started well. However, with the market remaining weak, particularly in Europe, and currency headwinds, we expect a similar performance in quarter four to that seen in the third quarter. Looking further forward, the Board remains confident that Croda has the right strategy for continued growth."

 

 

For further information please contact:

 

Steve Foots

Group Chief Executive

01405 860 551

Sean Christie

Group Finance Director

01405 860 551

Charlie Armitstead

Pendomer Communications

020 3603 5224

 

 

The company will host a conference call for analysts at 8.00am today.

 

Please dial +44 (0) 20 3140 0722 and quote "Croda International" to gain access to the call.

 

 

 

 

  

 

Additional Information

 

£m

Q3

9 months

2012

2011

2012

2011

Consumer Care

140.9

144.8

-2.7%

450.1

437.0

+3.0%

Performance Technologies

94.7

92.4

+2.5%

298.9

291.9

+2.4%

Industrial Chemicals

20.9

18.0

+16.1%

62.8

64.1

-2.0%

Continuing turnover

256.5

255.2

+0.5%

811.8

793.0

+2.4%

Consumer Care

44.2

41.8

+5.7%

140.9

128.6

+9.6%

Performance Technologies

13.4

13.7

-2.2%

46.3

42.5

+8.9%

Industrial Chemicals

2.1

1.5

 +40.0%

6.3

7.7

-18.2%

Continuing operating profit

59.7

57.0

+4.7%

193.5

178.8

+8.2%

Operating margin

 

23.3%

 

22.3%

 

 

 

23.8%

 

22.6%

 

 

 

Interest

(0.4)

(0.2)

(1.5)

(0.7)

Continuing pre tax profit

59.3

56.8

+4.4%

192.0

178.1

+7.8%

 

 

 

Analysis of Q3 turnover uplift

Volume

+8.9%

+3.5%

Price/mix

-5.7%

+0.7%

Underlying

+3.2%

+4.2%

Acquisition

+0.1%

-

Currency

-2.8%

-1.8%

Increase in continuing turnover

+0.5%

+2.4%

 

 

 

 

  

Supplementary analysis for continuing operations

30 September 2012

Unaudited £m

 

 

2012

2012

2012

Q1

Q2

Q3

Turnover

Consumer Care

159.1

150.1

140.9

Performance Technologies

102.7

101.5

94.7

Industrial Chemicals

20.1

21.8

20.9

281.9

273.4

256.5

Profits

Consumer Care

48.2

48.5

44.2

Performance Technologies

15.8

17.1

13.4

Industrial Chemicals

1.5

2.7

2.1

65.5

68.3

59.7

Interest

(0.7)

(0.4)

(0.4)

64.8

67.9

59.3

2011

2011

2011

2011

2011

Q1

Q2

Q3

Q4

Year

Turnover

Consumer Care

145.7

146.5

144.8

135.1

572.1

Performance Technologies

99.2

100.3

92.4

84.5

376.4

Industrial Chemicals

22.6

23.5

18.0

23.6

87.7

267.5

270.3

255.2

243.2

1,036.2

Profits

Consumer Care

41.8

45.0

41.8

42.6

171.2

Performance Technologies

14.6

14.2

13.7

12.8

55.3

Industrial Chemicals

2.7

3.5

1.5

3.5

11.2

59.1

62.7

57.0

58.9

237.7

Interest

(0.2)

(0.3)

(0.2)

0.5

(0.2)

58.9

62.4

56.8

59.4

237.5

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUASWRUVAROAA
Date   Source Headline
7th Nov 20227:00 amRNSJez Maiden to retire as Group Finance Director
3rd Nov 20225:53 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:50 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:49 pmRNSDirector/PDMR Shareholding
11th Oct 20221:37 pmRNSDirector/PDMR Shareholding
7th Oct 20228:37 amRNSDirector/PDMR Shareholding
7th Oct 20227:59 amRNSDirector/PDMR Shareholding
7th Oct 20227:00 amRNSInvestor seminar
5th Oct 20224:42 pmRNSDirector/PDMR Shareholding
20th Sep 20229:01 amRNSDirector/PDMR Shareholding
13th Sep 20221:47 pmRNSDirector/PDMR Shareholding
11th Aug 20222:39 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSResults for the six months ended 30 June 2022
22nd Jul 20224:50 pmRNSDirectorate Change
12th Jul 20223:08 pmRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSCompleted divestment
30th Jun 202212:15 pmRNSTotal Voting Rights
28th Jun 20227:00 amRNSUS Government to support lipid systems expansion
22nd Jun 20229:07 amRNSHolding(s) in Company
17th Jun 20229:46 amRNSHolding(s) in Company
13th Jun 20222:52 pmRNSDirector/PDMR Shareholding
8th Jun 202211:53 amRNSDirector/PDMR Shareholding
7th Jun 20225:23 pmRNSTransaction in Own Shares
7th Jun 20224:08 pmRNSDirector/PDMR Shareholding
7th Jun 20223:27 pmRNSHolding(s) in Company
27th May 202210:48 amRNSHolding(s) in Company
26th May 20227:02 amRNSDirector Declaration
23rd May 20222:34 pmRNSResult of AGM
20th May 20227:21 amRNSAGM trading update
19th May 20223:09 pmRNSDirector/PDMR Shareholding
19th May 20222:17 pmRNSHolding(s) in Company
11th May 20222:15 pmRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSSite visit and investor presentation
3rd May 202210:21 amRNSDirector/PDMR Shareholding
13th Apr 20229:48 amRNSDirector/PDMR Shareholding
7th Apr 20226:15 pmRNSDirector/PDMR Shareholding
31st Mar 20223:12 pmRNSUK Government to support lipid systems expansion
29th Mar 20227:00 amRNSInvestor seminar
22nd Mar 20226:14 pmRNSAnnual Financial Report
22nd Mar 20224:49 pmRNSDirector/PDMR Shareholding
16th Mar 20225:21 pmRNSDirector/PDMR Shareholding
16th Mar 20225:20 pmRNSDirector/PDMR Shareholding
16th Mar 20225:19 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:13 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.